These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36298632)

  • 1. Vaccine Adverse Events Following COVID-19 Vaccination with Inactivated Vaccines in Zimbabwe.
    Makadzange AT; Gundidza P; Lau C; Beta N; Myburgh N; Elose N; James W; Stanberry L; Ndhlovu C
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Actual Status of Hospitals as COVID-19 Vaccination Clinics in China and Safety Monitoring of Inactivated Vaccine: A Cross-Sectional Study.
    Huang J; Zhang MQ; Huang MZ; Lin GM
    Disaster Med Public Health Prep; 2022 Aug; 17():e256. PubMed ID: 36017705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Sinopharm vaccine for people with Multiple Sclerosis: Study of adverse reactions and disease activity.
    Kavosh A; Ashtari F; Naghavi S; Adibi I; Shaygannejad V; Karimi Z; Arabi S; Rahimi M; Mazaheri S
    Mult Scler Relat Disord; 2022 May; 61():103708. PubMed ID: 35349883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE-An Observational Study.
    Ganesan S; Al Ketbi LMB; Al Kaabi N; Al Mansoori M; Al Maskari NN; Al Shamsi MS; Alderei AS; El Eissaee HN; Al Ketbi RM; Al Shamsi NS; Saleh KM; Al Blooshi AF; Cantarutti FM; Warren K; Ahamed F; Zaher W
    Front Public Health; 2022; 10():876336. PubMed ID: 35602146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effects following COVID-19 vaccination in Iran.
    Babaee E; Amirkafi A; Tehrani-Banihashemi A; SoleimanvandiAzar N; Eshrati B; Rampisheh Z; Asadi-Aliabadi M; Nojomi M
    BMC Infect Dis; 2022 May; 22(1):476. PubMed ID: 35585518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis.
    Etemadifar M; Abhari AP; Nouri H; Sigari AA; Piran Daliyeh SM; Maracy MR; Salari M; Maleki S; Sedaghat N
    Hum Vaccin Immunother; 2022 Dec; 18(1):2041945. PubMed ID: 35201963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
    Rayamajhi S; Rafi MA; Tripathi N; Dongol AS; Pandey M; Rayamajhi S; Bhandari S; Shrestha P; Hasan MT; Hossain MG
    PLoS One; 2022; 17(8):e0272729. PubMed ID: 35947626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upper extremity deep vein thrombosis following BBIBP-CorV COVID-19 vaccine (Sinopharm vaccine): A case report.
    Riazi A; Faghih Dinevari M; Abbasian S; Jabbaripour Sarmadian A
    Clin Case Rep; 2023 Jun; 11(6):e7535. PubMed ID: 37323251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccination for patients with benign childhood epilepsy with centrotemporal spikes.
    Yang X; Wu L; Zheng D; Yang B; Wu D
    Epilepsy Behav; 2022 Sep; 134():108744. PubMed ID: 35952506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Effects Reported and Insights Following Sinopharm COVID-19 Vaccination.
    Mohebbi A; Eterafi M; Fouladi N; Golizadeh M; Panahizadeh R; Habibzadeh S; Karimi K; Safarzadeh E
    Curr Microbiol; 2023 Oct; 80(12):377. PubMed ID: 37861721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
    Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
    BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax;a Systematic Review.
    Dadras O; Mehraeen E; Karimi A; Tantuoyir MM; Afzalian A; Nazarian N; Mojdeganlou H; Mirzapour P; Shamsabadi A; Dashti M; Ghasemzadeh A; Vahedi F; Shobeiri P; Pashaei Z; SeyedAlinaghi S
    Arch Acad Emerg Med; 2022; 10(1):e54. PubMed ID: 36033990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects and perceptions following Sinopharm COVID-19 vaccination.
    Saeed BQ; Al-Shahrabi R; Alhaj SS; Alkokhardi ZM; Adrees AO
    Int J Infect Dis; 2021 Oct; 111():219-226. PubMed ID: 34384899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events following immunization of elderly with COVID-19 inactivated virus vaccine (CoronaVac) in Southeastern Brazil: an active surveillance study.
    Miyaji KT; Itto LYU; Jacintho LC; Sales ACR; Hiratsuka M; Leonel FC; Higa-Taniguchi KT; Picone CM; Lara AN; Rodrigues CCM; Lopes MH; Sartori AMC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e56. PubMed ID: 36197371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.